Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CMT-3. CollaGenex.

Barbara Fingleton1

  • 1Vanderbilt University Medical Center, Department of Cancer Biology, 736 Preston Research Building, 23rd and Pierce Avenues, Nashville, TN 37232-6840, USA. barbara.fingleton@Vanderbilt.Edu

Current Opinion in Investigational Drugs (London, England : 2000)
|February 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of tumor proliferation by unlocking silent synapses on metastatic cancer cells.

bioRxiv : the preprint server for biology·2026
Same author

TREM2 expressing macrophages are not associated with prognostic markers or metabolic syndrome in early stage ER positive breast cancer.

Scientific reports·2025
Same author

Loss of IL13RA2 promotes metastatic tumor growth in triple-negative breast cancer via increased AKT and NF-κB signaling.

Clinical & experimental metastasis·2025
Same author

Comparison of Lean, Obese, and Weight-Loss Models Reveals TREM2 Deficiency Attenuates Breast Cancer Growth Uniquely in Lean Mice and Alters Clonal T-cell Populations.

Cancer research·2025
Same author

Elucidating Sex-Specific Immune Profiles in a Breast Cancer Model.

International journal of molecular sciences·2024
Same author

Trem2 deficiency attenuates breast cancer tumor growth in lean, but not obese or weight loss, mice and is associated with alterations of clonal T cell populations.

bioRxiv : the preprint server for biology·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

CMT-3, an orally active matrix metalloprotease inhibitor, is being investigated for cancer treatment. Phase II trials are underway for metastatic cancer and Kaposi

Area of Science:

  • Pharmacology
  • Oncology
  • Virology

Background:

  • Matrix metalloproteinases (MMPs) play a role in cancer progression.
  • Cytokines are implicated in various diseases, including cancer and HIV.
  • CMT-3 is an investigational drug targeting MMPs and cytokines.

Purpose of the Study:

  • To evaluate the efficacy of CMT-3 in cancer treatment.
  • To assess CMT-3's potential in managing HIV-related conditions.

Main Methods:

  • CMT-3 is an orally administered matrix metalloprotease inhibitor.
  • The compound targets multiple proteases and cytokines.
  • Phase II clinical trials are being conducted.

Main Results:

Related Experiment Videos

  • CMT-3 is under development by CollaGenex.
  • The drug is being tested for potential cancer treatment.
  • Specific focus on metastatic cancer and Kaposi's sarcoma.

    • Conclusions:

    • CMT-3 shows promise as a therapeutic agent.
    • Further research is needed to confirm its clinical benefits.